Brian Reid
@brianreid.bsky.social
I have a newsletter. It's called Cost Curve. I write a lot about dull things like 340B reform and benefit design and the Value Flower.
You can probably Google it.
You can probably Google it.
Headline writers were kind of phoning it in yesterday. #takeaways
May 23, 2025 at 11:05 AM
Headline writers were kind of phoning it in yesterday. #takeaways
The @washingtonpost.com eddy board has a wildly pro-pharma editorial today.
Good to see innovation recognized.
wapo.st/4k4Pkx2
Good to see innovation recognized.
wapo.st/4k4Pkx2
May 20, 2025 at 8:47 PM
The @washingtonpost.com eddy board has a wildly pro-pharma editorial today.
Good to see innovation recognized.
wapo.st/4k4Pkx2
Good to see innovation recognized.
wapo.st/4k4Pkx2
@matt-levine.bsky.social nails how I think about video.
Like, I don't get the fascination, but it's hard not to see there is demand.
So yes, more dumb LinkedIn videos coming.
Like, I don't get the fascination, but it's hard not to see there is demand.
So yes, more dumb LinkedIn videos coming.
May 20, 2025 at 6:42 PM
@matt-levine.bsky.social nails how I think about video.
Like, I don't get the fascination, but it's hard not to see there is demand.
So yes, more dumb LinkedIn videos coming.
Like, I don't get the fascination, but it's hard not to see there is demand.
So yes, more dumb LinkedIn videos coming.
Is the CMS drug negotiation page down for anyone else?
May 12, 2025 at 4:19 PM
Is the CMS drug negotiation page down for anyone else?
Props to the Bloomberg photo-captions person.
April 22, 2025 at 11:43 AM
Props to the Bloomberg photo-captions person.
@maya-goldman.bsky.social with a scoop on the fate of a bunch of CMMI projects. Two as-yet-unlaunched drug-price demos got the axe.
Probably not a surprise, but clarifying nonetheless.
www.axios.com/2025/03/12/m...
Probably not a surprise, but clarifying nonetheless.
www.axios.com/2025/03/12/m...
March 12, 2025 at 9:14 PM
@maya-goldman.bsky.social with a scoop on the fate of a bunch of CMMI projects. Two as-yet-unlaunched drug-price demos got the axe.
Probably not a surprise, but clarifying nonetheless.
www.axios.com/2025/03/12/m...
Probably not a surprise, but clarifying nonetheless.
www.axios.com/2025/03/12/m...
Also a national treasure: @matt-levine.bsky.social.
February 24, 2025 at 7:50 PM
Also a national treasure: @matt-levine.bsky.social.
Love this. @nikillinit.bsky.social nails the #JPM25 ironies.
January 16, 2025 at 4:36 PM
Love this. @nikillinit.bsky.social nails the #JPM25 ironies.
The benefit design change part of the IRA -- the part that gives beneficiaries the $2,000 out-of-pocket cap in Part D -- is going to cost Pfizer a billion dollars next year.
That $500 million in boosted sales, less $1.5 billion in additional responsibilities in the catastrophic phase.
That $500 million in boosted sales, less $1.5 billion in additional responsibilities in the catastrophic phase.
December 18, 2024 at 2:59 PM
The benefit design change part of the IRA -- the part that gives beneficiaries the $2,000 out-of-pocket cap in Part D -- is going to cost Pfizer a billion dollars next year.
That $500 million in boosted sales, less $1.5 billion in additional responsibilities in the catastrophic phase.
That $500 million in boosted sales, less $1.5 billion in additional responsibilities in the catastrophic phase.